ISU ABXIS

Eucure Biopharma, a wholly-owned subsidiary of Sino-US contract research organization (CRO) Biocytogen, has entered into a partnership agreement with South Korea-based ISU ABXIS Co., Ltd (ISU ABXIS, KOSDAQ: 086890). Under the agreement, ISU ABXIS has been granted the use of Eucure’s YH003 sequence to develop multiple tri-specific antibodies for the…